Form 4: Ligand Pharmaceuticals Director Receives Equity Compensation Awards

Ligand Pharmaceuticals Inc. Director John L. LaMattina was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Summary

• John L. LaMattina, a Director of Ligand Pharmaceuticals Inc. (LGND), received equity grants on June 6, 2025.
• The grants include 1,209 restricted stock units (RSUs) and 5,783 non-qualified stock options.
• The RSUs were acquired at a price of $0.0, representing a contingent right to receive one share of common stock per RSU.
• The non-qualified stock options have an exercise price of $105.99 per share and expire on June 6, 2035.
• Both the RSUs and options were granted by the Board of Directors at their annual meeting on June 6, 2025.
• These awards will fully vest on the earlier of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.
• Following these transactions, Mr. LaMattina beneficially owns 30,724 shares of common stock and 5,783 non-qualified stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of ongoing compensation and alignment of interests, but does not contain significant new operational or financial news to warrant a higher score.

Positives

• The grant of equity awards to a director aligns management's interests with those of shareholders, promoting long-term value creation.
• The awards are part of standard compensation practices for directors, indicating continuity and stability in corporate governance.

Future Outlook

The granted restricted stock units and non-qualified stock options are subject to a vesting schedule, which will occur on the earlier of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date, indicating future changes in beneficial ownership upon vesting.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice in the pharmaceutical and biotechnology industries. Such grants are typically used to align the interests of company leadership with long-term shareholder value, reflecting standard corporate governance practices.

Comparison to Industry Standards

• Equity grants, including restricted stock units and stock options, are standard components of director compensation across various industries, including pharmaceuticals, aligning director incentives with company performance.
• The vesting schedule tied to either the next annual meeting or the first anniversary of the grant date is a common structure for director equity awards, similar to practices observed in comparable public companies.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Director John L. LaMattina constitutes a related party transaction, which is a standard component of director compensation.

Stakeholder Impact

• Shareholders: The equity grants to the director further align his interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is mentioned in this specific filing.

Next Steps

• Vesting of the granted restricted stock units and non-qualified stock options will occur on the earlier of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, Form 4, SEC filing, insider transaction, equity grant, restricted stock units, stock options, director compensation